Catalog No.: PC-38609Not For Human Use, Lab Use Only.
MYLS22 is a specific, nontoxic small molecule inhibitor of the inner mitochondrial membrane mitochondrial fusion protein optic atrophy 1 (OPA1), curtails tumor growth and metastasisin vitro and in vivo.
MYLS22 is a specific, nontoxic small molecule inhibitor of the inner mitochondrial membrane mitochondrial fusion protein optic atrophy 1 (OPA1), curtails tumor growth and metastasisin vitro and in vivo.
MYLS22 downregulates the angiogenic factors (FGFR, FGF, EGF, and PDGF) used by tumors escaping from VEGF inhibitors.
MYLS22 (peritumoral injection 10 mg/kg/die) curtailed tumor growth, did not display any additive effect in Opa1+/ΔEC mice.
Pharmacological OPA1 inhibition via MYLS22 reduces breast cancer hallmarks in vitro.
